Skip to main content
Top
Gepubliceerd in: Quality of Life Research 1/2017

24-10-2016 | Review

Assessment of the construct validity and responsiveness of preference-based quality of life measures in people with Parkinson’s: a systematic review

Auteurs: Yiqiao Xin, Emma McIntosh

Gepubliceerd in: Quality of Life Research | Uitgave 1/2017

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

Generic preference-based quality of life (PbQoL) measures are sometimes criticized for being insensitive or failing to capture important aspects of quality of life (QoL) in specific populations. The objective of this study was to systematically review and assess the construct validity and responsiveness of PbQoL measures in Parkinson’s.

Methods

Ten databases were systematically searched up to July 2015. Studies were included if a PbQoL instrument along with a common Parkinson’s clinical or QoL measure was used, and the utility values were reported. The PbQoL instruments were assessed for construct validity (discriminant and convergent validity) and responsiveness.

Results

Twenty-three of 2758 studies were included, of which the majority evidence was for EQ-5D. Overall good evidence of discriminant validity was demonstrated in the Health Utility Index (HUI)-3, EQ-5D-5L, EQ-5D-3L, 15D, HUI-2, and Disability and Distress Index (DDI). Nevertheless, HUI-2 and EQ-5D-3L were shown to be less sensitive among patients with mild Parkinson’s. Moderate to strong correlations were shown between the PbQoL measures (EQ-5D-3L, EQ-5D-5L, 15D, DDI, and HUI-II) and Parkinson’s-specific measures. Twelve studies provided evidence for the assessment of responsiveness of EQ-5D-3L and one study for 15D, among which six studies reached inconsistent results between EQ-5D-3L and the Parkinson’s-specific measures in measuring the change overtime.

Conclusions

The construct validity of the PbQoL measures was generally good, but there are concerns regarding their responsiveness to change. In Parkinson’s, the inclusion of a Parkinson’s-specific QoL measure or a generic but broader scoped mental and well-being focused measure to incorporate aspects not included in the common PbQoL measures is recommended.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
3.
go back to reference von Neumann, J., & Morgenstern, O. (1944). Theory of games and economic behaviour. Princeton: Princeton University Press. von Neumann, J., & Morgenstern, O. (1944). Theory of games and economic behaviour. Princeton: Princeton University Press.
4.
go back to reference Holloway, C. (1979). Decision making under uncertainty: models and choices. Englewood Cliffs: Prentice-Hall. Holloway, C. (1979). Decision making under uncertainty: models and choices. Englewood Cliffs: Prentice-Hall.
5.
go back to reference Torrance, G. W., Thomas, W. H., & Sackett, D. L. (1972). A utility maximization model for evaluation of health care programs. Health Service Research, 7(2), 118–133. Torrance, G. W., Thomas, W. H., & Sackett, D. L. (1972). A utility maximization model for evaluation of health care programs. Health Service Research, 7(2), 118–133.
6.
go back to reference EuroQol Group. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.CrossRef EuroQol Group. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.CrossRef
7.
go back to reference Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., et al. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20(10), 1727–1736.CrossRefPubMedPubMedCentral Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., et al. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20(10), 1727–1736.CrossRefPubMedPubMedCentral
8.
go back to reference Brazier, J., Roberts, J., & Deverill, M. (2002). The estimation of a preference-based measure of health from the SF-36. Journal of Health Economics, 21(2), 271–292.CrossRefPubMed Brazier, J., Roberts, J., & Deverill, M. (2002). The estimation of a preference-based measure of health from the SF-36. Journal of Health Economics, 21(2), 271–292.CrossRefPubMed
9.
go back to reference Torrance, G. W., Feeny, D. H., Furlong, W. J., Barr, R. D., Zhang, Y., & Wang, Q. (1996). Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Medical Care, 34(7), 702–722.CrossRefPubMed Torrance, G. W., Feeny, D. H., Furlong, W. J., Barr, R. D., Zhang, Y., & Wang, Q. (1996). Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Medical Care, 34(7), 702–722.CrossRefPubMed
10.
go back to reference Feeny, D., Furlong, W., Torrance, G. W., Goldsmith, C. H., Zhu, Z., DePauw, S., et al. (2002). Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Medical Care, 40(2), 113–128.CrossRefPubMed Feeny, D., Furlong, W., Torrance, G. W., Goldsmith, C. H., Zhu, Z., DePauw, S., et al. (2002). Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Medical Care, 40(2), 113–128.CrossRefPubMed
12.
go back to reference Brazier, J. (2010). Is the EQ-5D fit for purpose in mental health? British Journal of Psychiatry, 197(5), 348–349.CrossRefPubMed Brazier, J. (2010). Is the EQ-5D fit for purpose in mental health? British Journal of Psychiatry, 197(5), 348–349.CrossRefPubMed
13.
go back to reference Papaioannou, D., Brazier, J., & Parry, G. (2011). How valid and responsive are generic health status measures, such as EQ-5D and SF-36, in Schizophrenia? A systematic review. Value in Health, 14(6), 907–920.CrossRefPubMedPubMedCentral Papaioannou, D., Brazier, J., & Parry, G. (2011). How valid and responsive are generic health status measures, such as EQ-5D and SF-36, in Schizophrenia? A systematic review. Value in Health, 14(6), 907–920.CrossRefPubMedPubMedCentral
15.
go back to reference Riepe, M. W., Mittendorf, T., Forstl, H., Frolich, L., Haupt, M., Leidl, R., et al. (2009). Quality of life as an outcome in Alzheimer’s disease and other dementias–obstacles and goals. BMC Neurology, 9, 47.CrossRefPubMedPubMedCentral Riepe, M. W., Mittendorf, T., Forstl, H., Frolich, L., Haupt, M., Leidl, R., et al. (2009). Quality of life as an outcome in Alzheimer’s disease and other dementias–obstacles and goals. BMC Neurology, 9, 47.CrossRefPubMedPubMedCentral
16.
go back to reference Hounsome, N., Orrell, M., & Edwards, R. T. (2011). EQ-5D as a quality of life measure in people with dementia and their carers: evidence and key issues. Value in Health, 14(2), 390–399.CrossRefPubMed Hounsome, N., Orrell, M., & Edwards, R. T. (2011). EQ-5D as a quality of life measure in people with dementia and their carers: evidence and key issues. Value in Health, 14(2), 390–399.CrossRefPubMed
18.
go back to reference Longworth, L., Yang, Y., Young, T., Mulhern, B., Hernandez Alava, M., Mukuria, C., et al. (2014). Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technology Assessment, 18(9), 1–224.CrossRefPubMedPubMedCentral Longworth, L., Yang, Y., Young, T., Mulhern, B., Hernandez Alava, M., Mukuria, C., et al. (2014). Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technology Assessment, 18(9), 1–224.CrossRefPubMedPubMedCentral
19.
go back to reference Rowen, D., Mulhern, B., Banerjee, S., Tait, R., Watchurst, C., Smith, S. C., et al. (2015). Comparison of general population, patient, and carer utility values for dementia health states. Medical Decision Making, 35(1), 68–80.CrossRefPubMedPubMedCentral Rowen, D., Mulhern, B., Banerjee, S., Tait, R., Watchurst, C., Smith, S. C., et al. (2015). Comparison of general population, patient, and carer utility values for dementia health states. Medical Decision Making, 35(1), 68–80.CrossRefPubMedPubMedCentral
20.
go back to reference Moock, J., & Kohlmann, T. (2008). Comparing preference-based quality-of-life measures: results from rehabilitation patients with musculoskeletal, cardiovascular, or psychosomatic disorders. Quality of Life Research, 17(3), 485–495.CrossRefPubMed Moock, J., & Kohlmann, T. (2008). Comparing preference-based quality-of-life measures: results from rehabilitation patients with musculoskeletal, cardiovascular, or psychosomatic disorders. Quality of Life Research, 17(3), 485–495.CrossRefPubMed
21.
go back to reference Barton, G. R., Sach, T. H., Avery, A. J., Jenkinson, C., Doherty, M., Whynes, D. K., et al. (2008). A comparison of the performance of the EQ-5D and SF-6D for individuals aged > or = 45 years. Health Economics, 17(7), 815–832.CrossRefPubMed Barton, G. R., Sach, T. H., Avery, A. J., Jenkinson, C., Doherty, M., Whynes, D. K., et al. (2008). A comparison of the performance of the EQ-5D and SF-6D for individuals aged > or = 45 years. Health Economics, 17(7), 815–832.CrossRefPubMed
22.
go back to reference McDonough, C. M., Grove, M. R., Tosteson, T. D., Lurie, J. D., Hilibrand, A. S., & Tosteson, A. N. (2005). Comparison of EQ-5D, HUI, and SF-36-derived societal health state values among spine patient outcomes research trial (SPORT) participants. Quality of Life Research, 14(5), 1321–1332.CrossRefPubMedPubMedCentral McDonough, C. M., Grove, M. R., Tosteson, T. D., Lurie, J. D., Hilibrand, A. S., & Tosteson, A. N. (2005). Comparison of EQ-5D, HUI, and SF-36-derived societal health state values among spine patient outcomes research trial (SPORT) participants. Quality of Life Research, 14(5), 1321–1332.CrossRefPubMedPubMedCentral
23.
go back to reference Brazier, J., Roberts, J., Tsuchiya, A., & Busschbach, J. (2004). A comparison of the EQ-5D and SF-6D across seven patient groups. Health Economics, 13(9), 873–884.CrossRefPubMed Brazier, J., Roberts, J., Tsuchiya, A., & Busschbach, J. (2004). A comparison of the EQ-5D and SF-6D across seven patient groups. Health Economics, 13(9), 873–884.CrossRefPubMed
24.
go back to reference Macran, S., Weatherly, H., & Kind, P. (2003). Measuring population health: a comparison of three generic health status measures. Medical Care, 41(2), 218–231.PubMed Macran, S., Weatherly, H., & Kind, P. (2003). Measuring population health: a comparison of three generic health status measures. Medical Care, 41(2), 218–231.PubMed
25.
go back to reference Richardson, J., Khan, M. A., Iezzi, A., & Maxwell, A. (2015). Comparing and explaining differences in the magnitude, content, and sensitivity of utilities predicted by the EQ-5D, SF-6D, HUI 3, 15D, QWB, and AQoL-8D multiattribute utility instruments. Medical Decision Making, 35(3), 276–291.CrossRefPubMed Richardson, J., Khan, M. A., Iezzi, A., & Maxwell, A. (2015). Comparing and explaining differences in the magnitude, content, and sensitivity of utilities predicted by the EQ-5D, SF-6D, HUI 3, 15D, QWB, and AQoL-8D multiattribute utility instruments. Medical Decision Making, 35(3), 276–291.CrossRefPubMed
26.
go back to reference Jenkinson, C., Fitzpatrick, R., Peto, V., Harris, R., & Saunders, P. (2008). The Parkinson’s disease questionnaire PDQ-39 user manual (including PDQ-9 and PDQ summary index): Health Services Research Unit (2nd ed.). Oxford: University of Oxford. Jenkinson, C., Fitzpatrick, R., Peto, V., Harris, R., & Saunders, P. (2008). The Parkinson’s disease questionnaire PDQ-39 user manual (including PDQ-9 and PDQ summary index): Health Services Research Unit (2nd ed.). Oxford: University of Oxford.
27.
go back to reference Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R., & Hyman, N. (1997). The Parkinson’s disease questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age and Ageing, 26(5), 353–357.CrossRefPubMed Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R., & Hyman, N. (1997). The Parkinson’s disease questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age and Ageing, 26(5), 353–357.CrossRefPubMed
28.
go back to reference Brazier, J. E., Rowen, D., Mavranezouli, I., Tsuchiya, A., Young, T., Yang, Y., et al. (2012). Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome). Health Technology Assessment, 16(32), 1–114.CrossRef Brazier, J. E., Rowen, D., Mavranezouli, I., Tsuchiya, A., Young, T., Yang, Y., et al. (2012). Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome). Health Technology Assessment, 16(32), 1–114.CrossRef
29.
go back to reference Versteegh, M. M., Leunis, A., Uyl-de Groot, C. A., & Stolk, E. A. (2012). Condition-specific preference-based measures: benefit or burden? Value in Health, 15(3), 504–513.CrossRefPubMed Versteegh, M. M., Leunis, A., Uyl-de Groot, C. A., & Stolk, E. A. (2012). Condition-specific preference-based measures: benefit or burden? Value in Health, 15(3), 504–513.CrossRefPubMed
30.
go back to reference de Lau, L. M., & Breteler, M. M. (2006). Epidemiology of Parkinson’s disease. Lancet Neurology, 5(6), 525–535.CrossRefPubMed de Lau, L. M., & Breteler, M. M. (2006). Epidemiology of Parkinson’s disease. Lancet Neurology, 5(6), 525–535.CrossRefPubMed
31.
go back to reference Rahman, S., Griffin, H. J., Quinn, N. P., & Jahanshahi, M. (2008). Quality of life in Parkinson’s disease: The relative importance of the symptoms. Movement Disorders, 23(10), 1428–1434.CrossRefPubMed Rahman, S., Griffin, H. J., Quinn, N. P., & Jahanshahi, M. (2008). Quality of life in Parkinson’s disease: The relative importance of the symptoms. Movement Disorders, 23(10), 1428–1434.CrossRefPubMed
32.
go back to reference Gallagher, D. A., Lees, A. J., & Schrag, A. (2010). What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Movement Disorders, 25(15), 2493–2500.CrossRefPubMed Gallagher, D. A., Lees, A. J., & Schrag, A. (2010). What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Movement Disorders, 25(15), 2493–2500.CrossRefPubMed
33.
go back to reference Martinez-Martin, P., Rodriguez-Blazquez, C., Kurtis, M. M., & Chaudhuri, K. R. (2011). The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Movement Disorders, 26(3), 399–406.CrossRefPubMed Martinez-Martin, P., Rodriguez-Blazquez, C., Kurtis, M. M., & Chaudhuri, K. R. (2011). The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Movement Disorders, 26(3), 399–406.CrossRefPubMed
34.
go back to reference Chapuis, S., Ouchchane, L., Metz, O., Gerbaud, L., & Durif, F. (2005). Impact of the motor complications of Parkinson’s disease on the quality of life. Movement Disorders, 20(2), 224–230.CrossRefPubMed Chapuis, S., Ouchchane, L., Metz, O., Gerbaud, L., & Durif, F. (2005). Impact of the motor complications of Parkinson’s disease on the quality of life. Movement Disorders, 20(2), 224–230.CrossRefPubMed
35.
go back to reference Winter, Y., von Campenhausen, S., Gasser, J., Seppi, K., Reese, J. P., Pfeiffer, K. P., et al. (2010). Social and clinical determinants of quality of life in Parkinson’s disease in Austria: A cohort study. Journal of Neurology, 257(4), 638–645.CrossRefPubMed Winter, Y., von Campenhausen, S., Gasser, J., Seppi, K., Reese, J. P., Pfeiffer, K. P., et al. (2010). Social and clinical determinants of quality of life in Parkinson’s disease in Austria: A cohort study. Journal of Neurology, 257(4), 638–645.CrossRefPubMed
36.
go back to reference Behari, M., Srivastava, A. K., & Pandey, R. M. (2005). Quality of life in patients with Parkinson’s disease. Parkinsonism and Related Disorders, 11(4), 221–226.CrossRefPubMed Behari, M., Srivastava, A. K., & Pandey, R. M. (2005). Quality of life in patients with Parkinson’s disease. Parkinsonism and Related Disorders, 11(4), 221–226.CrossRefPubMed
37.
go back to reference Gomez-Esteban, J. C., Zarranz, J. J., Lezcano, E., Tijero, B., Luna, A., Velasco, F., et al. (2007). Influence of motor symptoms upon the quality of life of patients with Parkinson’s disease. European Neurology, 57(3), 161–165.CrossRefPubMed Gomez-Esteban, J. C., Zarranz, J. J., Lezcano, E., Tijero, B., Luna, A., Velasco, F., et al. (2007). Influence of motor symptoms upon the quality of life of patients with Parkinson’s disease. European Neurology, 57(3), 161–165.CrossRefPubMed
38.
go back to reference Saarni, S. I., Harkanen, T., Sintonen, H., Suvisaari, J., Koskinen, S., Aromaa, A., et al. (2006). The impact of 29 chronic conditions on health-related quality of life: A general population survey in Finland using 15D and EQ-5D. Quality of Life Research, 15(8), 1403–1414.CrossRefPubMed Saarni, S. I., Harkanen, T., Sintonen, H., Suvisaari, J., Koskinen, S., Aromaa, A., et al. (2006). The impact of 29 chronic conditions on health-related quality of life: A general population survey in Finland using 15D and EQ-5D. Quality of Life Research, 15(8), 1403–1414.CrossRefPubMed
39.
go back to reference Martinez-Martin, P., Jeukens-Visser, M., Lyons, K. E., Rodriguez-Blazquez, C., Selai, C., Siderowf, A., et al. (2011). Health-related quality-of-life scales in Parkinson’s disease: critique and recommendations. Movement Disorders, 26(13), 2371–2380.CrossRefPubMed Martinez-Martin, P., Jeukens-Visser, M., Lyons, K. E., Rodriguez-Blazquez, C., Selai, C., Siderowf, A., et al. (2011). Health-related quality-of-life scales in Parkinson’s disease: critique and recommendations. Movement Disorders, 26(13), 2371–2380.CrossRefPubMed
40.
go back to reference Soh, S. E., McGinley, J., & Morris, M. E. (2011). Measuring quality of life in Parkinson’s disease: Selection of-an-appropriate health-related quality of life instrument. Physiotherapy, 97(1), 83–89.CrossRefPubMed Soh, S. E., McGinley, J., & Morris, M. E. (2011). Measuring quality of life in Parkinson’s disease: Selection of-an-appropriate health-related quality of life instrument. Physiotherapy, 97(1), 83–89.CrossRefPubMed
41.
go back to reference Dodel, R., Jonsson, B., Reese, J. P., Winter, Y., Martinez-Martin, P., Holloway, R., et al. (2014). Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson’s disease. Movement Disorders, 29(2), 169–176.CrossRefPubMed Dodel, R., Jonsson, B., Reese, J. P., Winter, Y., Martinez-Martin, P., Holloway, R., et al. (2014). Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson’s disease. Movement Disorders, 29(2), 169–176.CrossRefPubMed
42.
go back to reference Martinez-Martin, P., Gil-Nagel, A., Gracia, L. M., Gomez, J. B., Martinez-Sarries, J., & Bermejo, F. (1994). Unified Parkinson’s disease rating scale characteristics and structure. The Cooperative Multicentric Group. Movement Disorders, 9(1), 76–83.CrossRefPubMed Martinez-Martin, P., Gil-Nagel, A., Gracia, L. M., Gomez, J. B., Martinez-Sarries, J., & Bermejo, F. (1994). Unified Parkinson’s disease rating scale characteristics and structure. The Cooperative Multicentric Group. Movement Disorders, 9(1), 76–83.CrossRefPubMed
43.
go back to reference Hoehn, M. M., & Yahr, M. D. (1967). Parkinsonism: Onset, progression and mortality. Neurology, 17(5), 427–442.CrossRefPubMed Hoehn, M. M., & Yahr, M. D. (1967). Parkinsonism: Onset, progression and mortality. Neurology, 17(5), 427–442.CrossRefPubMed
44.
go back to reference Maccorquodale, K., & Meehl, P. E. (1948). On a distinction between hypothetical constructs and intervening variables. Psychological Review, 55(2), 95–107.CrossRefPubMed Maccorquodale, K., & Meehl, P. E. (1948). On a distinction between hypothetical constructs and intervening variables. Psychological Review, 55(2), 95–107.CrossRefPubMed
45.
go back to reference Cronbach, L. J., & Meehl, P. E. (1955). Construct validity in psychological tests. Psychological Bulletin—American Psychological Association, 52(4), 281–302. Cronbach, L. J., & Meehl, P. E. (1955). Construct validity in psychological tests. Psychological Bulletin—American Psychological Association, 52(4), 281–302.
46.
go back to reference Tosh, J., Brazier, J., Evans, P., & Longworth, L. (2012). A review of generic preference-based measures of health-related quality of life in visual disorders. Value in Health, 15(1), 118–127.CrossRefPubMedPubMedCentral Tosh, J., Brazier, J., Evans, P., & Longworth, L. (2012). A review of generic preference-based measures of health-related quality of life in visual disorders. Value in Health, 15(1), 118–127.CrossRefPubMedPubMedCentral
47.
go back to reference Janssen, M. F., Pickard, A. S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., et al. (2013). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: A multi-country study. Quality of Life Research, 22(7), 1717–1727.CrossRefPubMed Janssen, M. F., Pickard, A. S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., et al. (2013). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: A multi-country study. Quality of Life Research, 22(7), 1717–1727.CrossRefPubMed
48.
go back to reference Bowling, A., & Ebrahim, S. (2005). Handbook of health research methods. Investigation, measurement and analysis. Open University Press, Maidenhead. Bowling, A., & Ebrahim, S. (2005). Handbook of health research methods. Investigation, measurement and analysis. Open University Press, Maidenhead.
49.
go back to reference Brazier, J., Deverill, M., Green, C., Harper, R., & Booth, A. (1999). A review of the use of health status measures in economic evaluation. Health Technology Assessment, 3(9), 1–164. Brazier, J., Deverill, M., Green, C., Harper, R., & Booth, A. (1999). A review of the use of health status measures in economic evaluation. Health Technology Assessment, 3(9), 1–164.
50.
go back to reference Hattie, J., & Cooksey, R. (1984). Procedures for assessing the validities of tests using the “known-groups” method. Applied Psychological Measurement, 8(3), 295–305.CrossRef Hattie, J., & Cooksey, R. (1984). Procedures for assessing the validities of tests using the “known-groups” method. Applied Psychological Measurement, 8(3), 295–305.CrossRef
51.
go back to reference Carmines, E. G., & Zeller, R. A. (1979). Reliability and validity assessment. Beverly Hills: Sage.CrossRef Carmines, E. G., & Zeller, R. A. (1979). Reliability and validity assessment. Beverly Hills: Sage.CrossRef
52.
go back to reference Beaton, D. E., Bombardier, C., Katz, J. N., & Wright, J. G. (2001). A taxonomy for responsiveness. Journal of Clinical Epidemiology, 54(12), 1204–1217.CrossRefPubMed Beaton, D. E., Bombardier, C., Katz, J. N., & Wright, J. G. (2001). A taxonomy for responsiveness. Journal of Clinical Epidemiology, 54(12), 1204–1217.CrossRefPubMed
53.
go back to reference Stratford, P. W., Binkley, J. M., Riddle, D. L., & Guyatt, G. H. (1998). Sensitivity to change of the Roland-Morris back pain questionnaire: Part 1. Physical Therapy, 78(11), 1186–1196.PubMed Stratford, P. W., Binkley, J. M., Riddle, D. L., & Guyatt, G. H. (1998). Sensitivity to change of the Roland-Morris back pain questionnaire: Part 1. Physical Therapy, 78(11), 1186–1196.PubMed
54.
go back to reference Benito-Leon, J., Cubo, E., & Coronell, C. (2012). Impact of apathy on health-related quality of life in recently diagnosed Parkinson’s disease: The ANIMO study. Movement Disorders, 27(2), 211–218.CrossRefPubMed Benito-Leon, J., Cubo, E., & Coronell, C. (2012). Impact of apathy on health-related quality of life in recently diagnosed Parkinson’s disease: The ANIMO study. Movement Disorders, 27(2), 211–218.CrossRefPubMed
55.
go back to reference Garcia-Gordillo, M. A., Del Pozo-Cruz, B., Adsuar, J. C., Sanchez-Martinez, F. I., & Abellan-Perpinan, J. M. (2013). Validation and comparison of 15-D and EQ-5D-5L instruments in a Spanish Parkinson’s disease population sample. Quality of Life Research, 23(4), 1315–1326.CrossRefPubMed Garcia-Gordillo, M. A., Del Pozo-Cruz, B., Adsuar, J. C., Sanchez-Martinez, F. I., & Abellan-Perpinan, J. M. (2013). Validation and comparison of 15-D and EQ-5D-5L instruments in a Spanish Parkinson’s disease population sample. Quality of Life Research, 23(4), 1315–1326.CrossRefPubMed
56.
go back to reference Jones, C. A., Pohar, S. L., & Patten, S. B. (2009). Major depression and health-related quality of life in Parkinson’s disease. General Hospital Psychiatry, 31(4), 334–340.CrossRefPubMed Jones, C. A., Pohar, S. L., & Patten, S. B. (2009). Major depression and health-related quality of life in Parkinson’s disease. General Hospital Psychiatry, 31(4), 334–340.CrossRefPubMed
57.
go back to reference Luo, N., Low, S., Lau, P. N., Au, W. L., & Tan, L. C. (2009). Is EQ-5D a valid quality of life instrument in patients with Parkinson’s disease? A study in Singapore. ANNALS Academy of Medicine Singapore, 38(6), 521–528. Luo, N., Low, S., Lau, P. N., Au, W. L., & Tan, L. C. (2009). Is EQ-5D a valid quality of life instrument in patients with Parkinson’s disease? A study in Singapore. ANNALS Academy of Medicine Singapore, 38(6), 521–528.
58.
go back to reference Martinez-Martin, P., Rodriguez-Blazquez, C., Forjaz, M. J., Alvarez-Sanchez, M., Arakaki, T., Bergareche-Yarza, A., et al. (2014). Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson’s disease patients. European Journal of Neurology, 21(3), 519–524.CrossRefPubMed Martinez-Martin, P., Rodriguez-Blazquez, C., Forjaz, M. J., Alvarez-Sanchez, M., Arakaki, T., Bergareche-Yarza, A., et al. (2014). Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson’s disease patients. European Journal of Neurology, 21(3), 519–524.CrossRefPubMed
59.
go back to reference Pohar, S. L., & Allyson Jones, C. (2009). The burden of Parkinson disease (PD) and concomitant comorbidities. Archives of Gerontology and Geriatrics, 49(2), 317–321.CrossRefPubMed Pohar, S. L., & Allyson Jones, C. (2009). The burden of Parkinson disease (PD) and concomitant comorbidities. Archives of Gerontology and Geriatrics, 49(2), 317–321.CrossRefPubMed
60.
go back to reference Rodriguez-Blazquez, C., Forjaz, M. J., Frades-Payo, B., de Pedro-Cuesta, J., & Martinez-Martin, P. (2010). Independent validation of the scales for outcomes in Parkinson’s disease-autonomic (SCOPA-AUT). European Journal of Neurology, 17(2), 194–201.CrossRefPubMed Rodriguez-Blazquez, C., Forjaz, M. J., Frades-Payo, B., de Pedro-Cuesta, J., & Martinez-Martin, P. (2010). Independent validation of the scales for outcomes in Parkinson’s disease-autonomic (SCOPA-AUT). European Journal of Neurology, 17(2), 194–201.CrossRefPubMed
61.
go back to reference Rodriguez-Blazquez, C., Rojo-Abuin, J. M., Alvarez-Sanchez, M., Arakaki, T., Bergareche-Yarza, A., Chade, A., et al. (2013). The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson’s disease. Parkinsonism & Related Disorders, 19(10), 889–893.CrossRef Rodriguez-Blazquez, C., Rojo-Abuin, J. M., Alvarez-Sanchez, M., Arakaki, T., Bergareche-Yarza, A., Chade, A., et al. (2013). The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson’s disease. Parkinsonism & Related Disorders, 19(10), 889–893.CrossRef
62.
go back to reference Siderowf, A., Ravina, B., & Glick, H. A. (2002). Preference-based quality-of-life in patients with Parkinson’s disease. Neurology, 59(1), 103–108.CrossRefPubMed Siderowf, A., Ravina, B., & Glick, H. A. (2002). Preference-based quality-of-life in patients with Parkinson’s disease. Neurology, 59(1), 103–108.CrossRefPubMed
63.
go back to reference Swinn, L., Schrag, A., Viswanathan, R., Bloem, B. R., Lees, A., & Quinn, N. (2003). Sweating dysfunction in Parkinson’s disease. Movement Disorders, 18(12), 1459–1463.CrossRefPubMed Swinn, L., Schrag, A., Viswanathan, R., Bloem, B. R., Lees, A., & Quinn, N. (2003). Sweating dysfunction in Parkinson’s disease. Movement Disorders, 18(12), 1459–1463.CrossRefPubMed
64.
go back to reference Daley, D. J., Deane, K. H., Gray, R. J., Clark, A. B., Pfeil, M., Sabanathan, K., et al. (2014). Adherence therapy improves medication adherence and quality of life in people with Parkinson’s disease: a randomised controlled trial. International Journal of Clinical Practice, 68(8), 963–971.CrossRefPubMed Daley, D. J., Deane, K. H., Gray, R. J., Clark, A. B., Pfeil, M., Sabanathan, K., et al. (2014). Adherence therapy improves medication adherence and quality of life in people with Parkinson’s disease: a randomised controlled trial. International Journal of Clinical Practice, 68(8), 963–971.CrossRefPubMed
65.
go back to reference Ebersbach, G., Hahn, K., Lorrain, M., & Storch, A. (2010). Tolcapone improves sleep in patients with advanced Parkinson’s disease (PD). Archives of Gerontology and Geriatrics, 51(3), e125–e128.CrossRefPubMed Ebersbach, G., Hahn, K., Lorrain, M., & Storch, A. (2010). Tolcapone improves sleep in patients with advanced Parkinson’s disease (PD). Archives of Gerontology and Geriatrics, 51(3), e125–e128.CrossRefPubMed
66.
go back to reference Jarman, B., Hurwitz, B., Cook, A., Bajekal, M., & Lee, A. (2002). Effects of community based nurses specialising in Parkinson’s disease on health outcome and costs: Randomised controlled trial. BMJ, 324(7345), 1072–1075.CrossRefPubMedPubMedCentral Jarman, B., Hurwitz, B., Cook, A., Bajekal, M., & Lee, A. (2002). Effects of community based nurses specialising in Parkinson’s disease on health outcome and costs: Randomised controlled trial. BMJ, 324(7345), 1072–1075.CrossRefPubMedPubMedCentral
67.
go back to reference Larisch, A., Reuss, A., Oertel, W. H., & Eggert, K. (2011). Does the clinical practice guideline on Parkinson’s disease change health outcomes? A cluster randomized controlled trial. Journal of Neurology, 258(5), 826–834.CrossRefPubMed Larisch, A., Reuss, A., Oertel, W. H., & Eggert, K. (2011). Does the clinical practice guideline on Parkinson’s disease change health outcomes? A cluster randomized controlled trial. Journal of Neurology, 258(5), 826–834.CrossRefPubMed
68.
go back to reference Luo, N., Ng, W. Y., Lau, P. N., Au, W. L., & Tan, L. C. (2010). Responsiveness of the EQ-5D and 8-item Parkinson’s disease questionnaire (PDQ-8) in a 4-year follow-up study. Quality of Life Research, 19(4), 565–569.CrossRefPubMed Luo, N., Ng, W. Y., Lau, P. N., Au, W. L., & Tan, L. C. (2010). Responsiveness of the EQ-5D and 8-item Parkinson’s disease questionnaire (PDQ-8) in a 4-year follow-up study. Quality of Life Research, 19(4), 565–569.CrossRefPubMed
69.
go back to reference Noyes, K., Dick, A. W., & Holloway, R. G. (2006). Pramipexole versus levodopa in patients with early Parkinson’s disease: Effect on generic and disease-specific quality of life. Value in Health, 9(1), 28–38.CrossRefPubMed Noyes, K., Dick, A. W., & Holloway, R. G. (2006). Pramipexole versus levodopa in patients with early Parkinson’s disease: Effect on generic and disease-specific quality of life. Value in Health, 9(1), 28–38.CrossRefPubMed
70.
go back to reference Nyholm, D., Nilsson Remahl, A. I., Dizdar, N., Constantinescu, R., Holmberg, B., Jansson, R., et al. (2005). Duodenal levodopa infusion monotherapy versus oral polypharmacy in advanced Parkinson disease. Neurology, 64(2), 216–223.CrossRefPubMed Nyholm, D., Nilsson Remahl, A. I., Dizdar, N., Constantinescu, R., Holmberg, B., Jansson, R., et al. (2005). Duodenal levodopa infusion monotherapy versus oral polypharmacy in advanced Parkinson disease. Neurology, 64(2), 216–223.CrossRefPubMed
71.
go back to reference Reuther, M., Spottke, E. A., Klotsche, J., Riedel, O., Peter, H., Berger, K., et al. (2007). Assessing health-related quality of life in patients with Parkinson’s disease in a prospective longitudinal study. Parkinsonism & Related Disorders, 13(2), 108–114.CrossRef Reuther, M., Spottke, E. A., Klotsche, J., Riedel, O., Peter, H., Berger, K., et al. (2007). Assessing health-related quality of life in patients with Parkinson’s disease in a prospective longitudinal study. Parkinsonism & Related Disorders, 13(2), 108–114.CrossRef
72.
go back to reference Schroder, S., Martus, P., Odin, P., & Schaefer, M. (2012). Impact of community pharmaceutical care on patient health and quality of drug treatment in Parkinson’s disease. International Journal of Clinical Pharmacy, 34(5), 746–756.CrossRefPubMed Schroder, S., Martus, P., Odin, P., & Schaefer, M. (2012). Impact of community pharmaceutical care on patient health and quality of drug treatment in Parkinson’s disease. International Journal of Clinical Pharmacy, 34(5), 746–756.CrossRefPubMed
73.
go back to reference Stocchi, F., Giorgi, L., Hunter, B., & Schapira, A. H. (2011). PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson’s disease. Movement Disorders, 26(7), 1259–1265.CrossRefPubMed Stocchi, F., Giorgi, L., Hunter, B., & Schapira, A. H. (2011). PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson’s disease. Movement Disorders, 26(7), 1259–1265.CrossRefPubMed
74.
go back to reference Trend, P., Kaye, J., Gage, H., Owen, C., & Wade, D. (2002). Short-term effectiveness of intensive multidisciplinary rehabilitation for people with Parkinson’s disease and their carers. Clinical Rehabilitation, 16(7), 717–725.CrossRefPubMed Trend, P., Kaye, J., Gage, H., Owen, C., & Wade, D. (2002). Short-term effectiveness of intensive multidisciplinary rehabilitation for people with Parkinson’s disease and their carers. Clinical Rehabilitation, 16(7), 717–725.CrossRefPubMed
75.
go back to reference Wade, D. T., Gage, H., Owen, C., Trend, P., Grossmith, C., & Kaye, J. (2003). Multidisciplinary rehabilitation for people with Parkinson’s disease: A randomised controlled study. Journal of Neurology, Neurosurgery and Psychiatry, 74(2), 158–162.CrossRefPubMedPubMedCentral Wade, D. T., Gage, H., Owen, C., Trend, P., Grossmith, C., & Kaye, J. (2003). Multidisciplinary rehabilitation for people with Parkinson’s disease: A randomised controlled study. Journal of Neurology, Neurosurgery and Psychiatry, 74(2), 158–162.CrossRefPubMedPubMedCentral
76.
go back to reference Zhu, X. L., Chan, D. T., Lau, C. K., Poon, W. S., Mok, V. C., Chan, A. Y., et al. (2014). Cost-effectiveness of subthalmic nucleus deep brain stimulation for the treatment of advanced Parkinson disease in Hong Kong: A prospective study. World Neurosurgery, 82(6), 987–993.CrossRefPubMed Zhu, X. L., Chan, D. T., Lau, C. K., Poon, W. S., Mok, V. C., Chan, A. Y., et al. (2014). Cost-effectiveness of subthalmic nucleus deep brain stimulation for the treatment of advanced Parkinson disease in Hong Kong: A prospective study. World Neurosurgery, 82(6), 987–993.CrossRefPubMed
77.
go back to reference Rosser, R. M., & Watts, V. C. (1972). The measurement of hospital output. International Journal of Epidemiology, 1(4), 361–368.CrossRefPubMed Rosser, R. M., & Watts, V. C. (1972). The measurement of hospital output. International Journal of Epidemiology, 1(4), 361–368.CrossRefPubMed
78.
go back to reference Rosser, R., & Kind, P. (1978). A scale of valuations of states of illness: Is there a social consensus? International Journal of Epidemiology, 7(4), 347–358.CrossRefPubMed Rosser, R., & Kind, P. (1978). A scale of valuations of states of illness: Is there a social consensus? International Journal of Epidemiology, 7(4), 347–358.CrossRefPubMed
80.
go back to reference Sintonen, H. (2001). The 15D instrument of health-related quality of life: Properties and applications. Annals of Medicine, 33(5), 328–336.CrossRefPubMed Sintonen, H. (2001). The 15D instrument of health-related quality of life: Properties and applications. Annals of Medicine, 33(5), 328–336.CrossRefPubMed
81.
go back to reference Kristiansen, I. S., Bingefors, K., Nyholm, D., & Isacson, D. (2009). Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson’s disease in Sweden: An exploratory study. Applied Health Economics and Health Policy, 7(3), 167–180.CrossRefPubMed Kristiansen, I. S., Bingefors, K., Nyholm, D., & Isacson, D. (2009). Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson’s disease in Sweden: An exploratory study. Applied Health Economics and Health Policy, 7(3), 167–180.CrossRefPubMed
82.
go back to reference Lundqvist, C., Beiske, A. G., Reiertsen, O., & Kristiansen, I. S. (2014). Real life cost and quality of life associated with continuous intraduodenal levodopa infusion compared with oral treatment in Parkinson patients. Journal of Neurology, 261(12), 2438–2445.CrossRefPubMed Lundqvist, C., Beiske, A. G., Reiertsen, O., & Kristiansen, I. S. (2014). Real life cost and quality of life associated with continuous intraduodenal levodopa infusion compared with oral treatment in Parkinson patients. Journal of Neurology, 261(12), 2438–2445.CrossRefPubMed
83.
go back to reference Martinez-Martin, P., Rodriguez-Blazquez, C., Abe, K., Bhattacharyya, K. B., Bloem, B. R., Carod-Artal, F. J., et al. (2009). International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology, 73(19), 1584–1591.CrossRefPubMed Martinez-Martin, P., Rodriguez-Blazquez, C., Abe, K., Bhattacharyya, K. B., Bloem, B. R., Carod-Artal, F. J., et al. (2009). International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology, 73(19), 1584–1591.CrossRefPubMed
84.
go back to reference Soh, S.-E., Morris, M. E., & McGinley, J. L. (2011). Determinants of health-related quality of life in Parkinson’s disease: A systematic review. Parkinsonism & Related Disorders, 17(1), 1–9.CrossRef Soh, S.-E., Morris, M. E., & McGinley, J. L. (2011). Determinants of health-related quality of life in Parkinson’s disease: A systematic review. Parkinsonism & Related Disorders, 17(1), 1–9.CrossRef
85.
go back to reference McDonough, C. M., & Tosteson, A. N. (2007). Measuring preferences for cost-utility analysis: How choice of method may influence decision-making. Pharmacoeconomics, 25(2), 93–106.CrossRefPubMedPubMedCentral McDonough, C. M., & Tosteson, A. N. (2007). Measuring preferences for cost-utility analysis: How choice of method may influence decision-making. Pharmacoeconomics, 25(2), 93–106.CrossRefPubMedPubMedCentral
86.
go back to reference Yang, Y., Brazier, J. E., Tsuchiya, A., & Young, T. A. (2011). Estimating a preference-based index for a 5-dimensional health state classification for asthma derived from the asthma quality of life questionnaire. Medical Decision Making, 31(2), 281–291.CrossRefPubMed Yang, Y., Brazier, J. E., Tsuchiya, A., & Young, T. A. (2011). Estimating a preference-based index for a 5-dimensional health state classification for asthma derived from the asthma quality of life questionnaire. Medical Decision Making, 31(2), 281–291.CrossRefPubMed
87.
go back to reference Brazier, J., Czoski-Murray, C., Roberts, J., Brown, M., Symonds, T., & Kelleher, C. (2008). Estimation of a preference-based index from a condition-specific measure: The King’s Health Questionnaire. Medical Decision Making, 28(1), 113–126.CrossRefPubMed Brazier, J., Czoski-Murray, C., Roberts, J., Brown, M., Symonds, T., & Kelleher, C. (2008). Estimation of a preference-based index from a condition-specific measure: The King’s Health Questionnaire. Medical Decision Making, 28(1), 113–126.CrossRefPubMed
88.
go back to reference Brazier, J., & Tsuchiya, A. (2010). Preference-based condition-specific measures of health: What happens to cross programme comparability? Health Economics, 19(2), 125–129.CrossRefPubMed Brazier, J., & Tsuchiya, A. (2010). Preference-based condition-specific measures of health: What happens to cross programme comparability? Health Economics, 19(2), 125–129.CrossRefPubMed
89.
go back to reference Luo, N., Johnson, J. A., Shaw, J. W., & Coons, S. J. (2009). Relative efficiency of the EQ-5D, HUI2, and HUI3 index scores in measuring health burden of chronic medical conditions in a population health survey in the United States. Medical Care, 47(1), 53–60.CrossRefPubMed Luo, N., Johnson, J. A., Shaw, J. W., & Coons, S. J. (2009). Relative efficiency of the EQ-5D, HUI2, and HUI3 index scores in measuring health burden of chronic medical conditions in a population health survey in the United States. Medical Care, 47(1), 53–60.CrossRefPubMed
90.
go back to reference McDonough, C. M., Tosteson, T. D., Tosteson, A. N., Jette, A. M., Grove, M. R., & Weinstein, J. N. (2011). A longitudinal comparison of 5 preference-weighted health state classification systems in persons with intervertebral disk herniation. Medical Decision Making, 31(2), 270–280.CrossRefPubMed McDonough, C. M., Tosteson, T. D., Tosteson, A. N., Jette, A. M., Grove, M. R., & Weinstein, J. N. (2011). A longitudinal comparison of 5 preference-weighted health state classification systems in persons with intervertebral disk herniation. Medical Decision Making, 31(2), 270–280.CrossRefPubMed
91.
go back to reference Sung, L., Greenberg, M. L., Doyle, J. J., Young, N. L., Ingber, S., Rubenstein, J., et al. (2003). Construct validation of the health utilities index and the child health questionnaire in children undergoing cancer chemotherapy. British Journal of Cancer, 88(8), 1185–1190.CrossRefPubMedPubMedCentral Sung, L., Greenberg, M. L., Doyle, J. J., Young, N. L., Ingber, S., Rubenstein, J., et al. (2003). Construct validation of the health utilities index and the child health questionnaire in children undergoing cancer chemotherapy. British Journal of Cancer, 88(8), 1185–1190.CrossRefPubMedPubMedCentral
92.
go back to reference Peto, V., Jenkinson, C., & Fitzpatrick, R. (2001). Determining minimally important differences for the PDQ-39 Parkinson’s disease questionnaire. Age and Ageing, 30(4), 299–302.CrossRefPubMed Peto, V., Jenkinson, C., & Fitzpatrick, R. (2001). Determining minimally important differences for the PDQ-39 Parkinson’s disease questionnaire. Age and Ageing, 30(4), 299–302.CrossRefPubMed
93.
go back to reference Winter, Y., Lubbe, D., Oertel, W. H., & Dodel, R. (2012). Determining minimal clinically important difference for healthrelated quality of life scales in Parkinson’s disease. Movement Disorders, 27, S106.CrossRef Winter, Y., Lubbe, D., Oertel, W. H., & Dodel, R. (2012). Determining minimal clinically important difference for healthrelated quality of life scales in Parkinson’s disease. Movement Disorders, 27, S106.CrossRef
94.
go back to reference Ware, J. E., Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.CrossRefPubMed Ware, J. E., Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.CrossRefPubMed
95.
go back to reference Welsh, M., McDermott, M. P., Holloway, R. G., Plumb, S., Pfeiffer, R., & Hubble, J. (2003). Development and testing of the Parkinson’s disease quality of life scale. Movement Disorders, 18(6), 637–645.CrossRefPubMed Welsh, M., McDermott, M. P., Holloway, R. G., Plumb, S., Pfeiffer, R., & Hubble, J. (2003). Development and testing of the Parkinson’s disease quality of life scale. Movement Disorders, 18(6), 637–645.CrossRefPubMed
96.
go back to reference de Boer, A. G., Wijker, W., Speelman, J. D., & de Haes, J. C. (1996). Quality of life in patients with Parkinson’s disease: Development of a questionnaire. Journal of Neurology, Neurosurgery and Psychiatry, 61(1), 70–74.CrossRefPubMedPubMedCentral de Boer, A. G., Wijker, W., Speelman, J. D., & de Haes, J. C. (1996). Quality of life in patients with Parkinson’s disease: Development of a questionnaire. Journal of Neurology, Neurosurgery and Psychiatry, 61(1), 70–74.CrossRefPubMedPubMedCentral
Metagegevens
Titel
Assessment of the construct validity and responsiveness of preference-based quality of life measures in people with Parkinson’s: a systematic review
Auteurs
Yiqiao Xin
Emma McIntosh
Publicatiedatum
24-10-2016
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 1/2017
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-016-1428-x

Andere artikelen Uitgave 1/2017

Quality of Life Research 1/2017 Naar de uitgave